Oxford BioTherapeutics Partners with Bristol Myers Squibb to Develop Next-Generation T-Cell Engagers for Solid Tumors
核心洞察
Oxford BioTherapeutics (搜索) announced a multi-year strategic collaboration with Bristol Myers Squibb (搜索) to discover and develop novel T-cell engager (搜索) therapies for solid tumors (搜索) using OBT's proprietary OGAP-Verify platform.
The partnership marks OBT's third major pharmaceutical collaboration within 12 months, following strategic agreements with GSK and Roche in 2025, demonstrating strong validation of the OGAP-Verify platform.
Under the agreement, OBT will receive upfront payments and be eligible for milestone payments and royalties, while taking responsibility for discovery through development candidate delivery before BMS leads subsequent activities.
Oxford BioTherapeutics (搜索), a clinical-stage oncology company, has entered into a multi-year strategic collaboration with Bristol Myers Squibb (搜索) focused on discovering and developing novel T-cell engager (搜索) therapies for solid tumors (搜索). The partnership, announced on April 9, 2026, leverages OBT's proprietary OGAP-Verify discovery platform alongside BMS's oncology expertise to advance selected novel oncology targets (搜索).
Platform-Driven Target Discovery
The collaboration centers on OBT's OGAP-Verify target discovery and validation platform, which will be used to identify novel, tumor-selective targets (搜索) for solid cancers and generate next-generation T-cell engager (搜索) molecules. According to the companies, the platform enables highly sensitive identification of oncology targets (搜索) with improved attributes for drug development, supporting the creation of differentiated antibody-based therapies.
The partnership extends beyond traditional discovery arrangements, with OBT assuming responsibility for the design and delivery of development candidates. This expanded role highlights the company's evolution into a fully integrated discovery and preclinical development platform. Following OBT's delivery of development candidates, Bristol Myers Squibb (搜索) will lead subsequent research, development, and commercialization activities.
Financial Terms and Strategic Validation
Under the agreement terms, OBT will receive an upfront payment inclusive of research funding, with potential for significant downstream milestone payments and royalties on commercialized products from BMS. The companies did not disclose specific financial details.
The Bristol Myers Squibb (搜索) collaboration represents OBT's third partnership with a major pharmaceutical company within the past 12 months, following strategic partnerships with GSK and Roche in 2025. This rapid succession of major pharmaceutical partnerships reflects strong validation of the OGAP-Verify platform's potential to drive oncology innovation.
Leadership Perspective
"Collaborating with Bristol Myers Squibb (搜索), a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies," said Christian Rohlff, PhD, Chief Executive Officer of OBT. "This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumor-selective targets (搜索) and reflects the growing confidence in our ability to translate that science into development-ready therapeutic candidates."
Rohlff emphasized the complementary nature of the partnership, stating, "By combining OGAP-Verify's discovery and validation capabilities with Bristol Myers Squibb (搜索)'s expertise in translating oncology innovation into clinical and commercial outcomes, we are confident that together we can advance a new generation of innovative cancer (搜索) therapies that have the potential to make a meaningful difference for patients."
Company Background and Pipeline
Oxford BioTherapeutics (搜索) focuses on discovering and developing first-in-class antibody-based therapies designed to address major unmet patient needs in cancer (搜索) therapy. The company's therapeutic approaches include bispecific antibodies (搜索), antibody drug conjugate (搜索) (ADC) therapeutics, and targeted radiopharmaceuticals (搜索).
The company's pipeline and development capabilities have been validated through multiple strategic partnerships, including collaborations with Bristol Myers Squibb (搜索), GSK, Roche, Boehringer Ingelheim, and Zymeworks. Three programs originating from the OGAP technology are currently in clinical development in the United States and Europe.
OBT aims to broaden access to precision oncology by equipping industry partners with tools and insights needed to deliver novel, effective cancer (搜索) therapies to more patients more quickly. The OGAP-Verify platform's enhanced sensitivity, specificity, and reliability has the potential to significantly accelerate biopharma's capabilities to identify and validate human targets with robust scientific support.